Loading...
Market
Story
Amgen to Launch Biosimilar of Regeneron's Eylea After Tuesday Court Ruling
Oct 22, 2024, 07:13 PM
Amgen has announced the launch of its biosimilar version of Regeneron's blockbuster eye care drug Eylea. This follows a ruling by the U.S. appeals court in favor of Amgen on Tuesday, which denied Regeneron's motion for a preliminary injunction to block the biosimilar. An Amgen spokesperson said this decision marks a significant development in the pharmaceutical industry, particularly in the market for eye care treatments.
View original story
Similar markets
Pfizer wins the appeal • 25%
AstraZeneca wins the appeal • 25%
Settlement reached before appeal decision • 25%
Appeal dismissed • 25%
Decision upheld • 25%
Decision overturned • 25%
New trial ordered • 25%
No appeal filed • 25%
Yes • 50%
No • 50%
Fine upheld • 25%
Fine reduced • 25%
Fine overturned • 25%
Appeal withdrawn • 25%
Verdict upheld • 25%
Verdict overturned • 25%
Settlement reached • 25%
Other • 25%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
Decision upheld • 25%
Decision overturned • 25%
Modified ruling • 25%
No appeal filed • 25%
Sentence upheld • 25%
Sentence reduced • 25%
Sentence increased • 25%
New trial ordered • 25%
Verdict upheld • 25%
Verdict overturned • 25%
Settlement reached • 25%
Other • 25%
Yes • 50%
No • 50%
Roche wins • 25%
Stanford and Foresight win • 25%
Settlement reached • 25%
Case dismissed • 25%